PURPOSE: To determine the predictive value of urinary levels of two angiogenic factors, vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMPs), in a longitudinal study to determine their correlation with 1-year progression-free survival in patients with cancer. PATIENTS AND METHODS: VEGF and MMP levels were measured in the urine of 65 cancer patients at first evaluation, during therapy, and at follow-up (n = 242); normalized by creatinine levels; and compared with 16 healthy controls. The correlation of initial levels and trends of VEGF and MMPs with 1-year progression-free survival was assessed using two-sample tests and stepwise logistic regression. RESULTS: Urinary VEGF levels at presentation were different between patients with local-regional cancer and normal controls, and between patients with metastatic prostate cancer and local-regional disease (P =.04 and.01, respectively). Similar results were found with MMP measurement (P =.03 and.0001, respectively). Of those patients subsequently treated with radiation, VEGF levels at presentation between patients with no evidence of disease (NED) after radiation and those who had persistent or recurrent disease after radiotherapy were also different (P =.039). The comparison between angiogenic factor levels taken at least 1 month postradiotherapy and the last level taken during treatment was the strongest predictor of patient 1-year progression-free survival (P =.004). Similarly, the overall MMP trend was also significantly associated with 1-year progression-free survival, as was the individual MMP-2 trend (P =.004 and.001, respectively). Stepwise logistic regression revealed that the VEGF trend comparing postradiation levels with last level taken during treatment was an independent predictor of progression-free survival (P =.02). CONCLUSION: This small exploratory study suggests that the angiogenic urinary trends of VEGF and MMPs may be useful predictive markers for progression-free survival in cancer patients after the completion of radiotherapy.
PURPOSE: To determine the predictive value of urinary levels of two angiogenic factors, vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMPs), in a longitudinal study to determine their correlation with 1-year progression-free survival in patients with cancer. PATIENTS AND METHODS: VEGF and MMP levels were measured in the urine of 65 cancerpatients at first evaluation, during therapy, and at follow-up (n = 242); normalized by creatinine levels; and compared with 16 healthy controls. The correlation of initial levels and trends of VEGF and MMPs with 1-year progression-free survival was assessed using two-sample tests and stepwise logistic regression. RESULTS: Urinary VEGF levels at presentation were different between patients with local-regional cancer and normal controls, and between patients with metastatic prostate cancer and local-regional disease (P =.04 and.01, respectively). Similar results were found with MMP measurement (P =.03 and.0001, respectively). Of those patients subsequently treated with radiation, VEGF levels at presentation between patients with no evidence of disease (NED) after radiation and those who had persistent or recurrent disease after radiotherapy were also different (P =.039). The comparison between angiogenic factor levels taken at least 1 month postradiotherapy and the last level taken during treatment was the strongest predictor of patient 1-year progression-free survival (P =.004). Similarly, the overall MMP trend was also significantly associated with 1-year progression-free survival, as was the individual MMP-2 trend (P =.004 and.001, respectively). Stepwise logistic regression revealed that the VEGF trend comparing postradiation levels with last level taken during treatment was an independent predictor of progression-free survival (P =.02). CONCLUSION: This small exploratory study suggests that the angiogenic urinary trends of VEGF and MMPs may be useful predictive markers for progression-free survival in cancerpatients after the completion of radiotherapy.
Authors: Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael Leblanc; Richard I Fisher; Thomas P Miller Journal: Leuk Lymphoma Date: 2009-05
Authors: Dan G Duda; Christopher G Willett; Marek Ancukiewicz; Emmanuelle di Tomaso; Mira Shah; Brian G Czito; Rex Bentley; Martin Poleski; Gregory Y Lauwers; Madeline Carroll; Douglas Tyler; Christopher Mantyh; Paul Shellito; Jeffrey W Clark; Rakesh K Jain Journal: Oncologist Date: 2010-05-18
Authors: LaCreis R Kidd; Guy N Brock; Tiva T VanCleave; Marnita L Benford; Nicole A Lavender; Traci L Kruer; James L Wittliff Journal: Cancer Causes Control Date: 2010-06-23 Impact factor: 2.506
Authors: Evan J Wuthrick; Mitchell Kamrava; Walter J Curran; Maria Werner-Wasik; Kevin A Camphausen; Terry Hyslop; Rita Axelrod; David W Andrews; Jon Glass; Mitchell Machtay; Adam P Dicker Journal: Cancer Date: 2011-06-03 Impact factor: 6.860
Authors: Nathan A Wigner; Nitin Kulkarni; Mark Yakavonis; Megan Young; Brian Tinsley; Brett Meeks; Thomas A Einhorn; Louis C Gerstenfeld Journal: Injury Date: 2012-03 Impact factor: 2.586